98%
921
2 minutes
20
Study Objectives: This study compares the demographic characteristics and experiences of three different groups of adolescent and young adults (AYAs) seeking non-sedated intrauterine device (IUD) insertion in the outpatient setting: (1) cisgender individuals, (2) transgender and gender diverse (TGD) individuals receiving gender-affirming testosterone therapy, and (3) TGD individuals not receiving gender-affirming testosterone therapy.
Methods: This retrospective cohort study included AYAs age 13 to 21 years seeking IUD insertion. Data were obtained from the electronic health record via a pre-existing, multi-institutional shared quality improvement (QI) collaborative. The patient population was characterized by descriptive statistics; inferential statistics compared procedural complications, outcomes and patient-reported side effects. Unadjusted Kaplan-Meier and Cox proportional-hazard modeling assessed continuation rates.
Results: Of the 683 participants attempting IUD insertion, 623 were cisgender individuals, 18 were TGD individuals on gender-affirming testosterone, and 54 were TGD individuals not on testosterone. There was no difference in insertion indication (p=0.25). TGD patients on testosterone were more likely to have experienced a procedural adverse event (17%; p=0.04), and to have reported pain beyond expectation (p=0.003), although insertional success did not differ significantly between groups (p=0.22).
Conclusion: TGD AYAs had similar reasons as cisgender patients for seeking the IUD. While TGD individuals on testosterone were more likely to have pain or an adverse procedural event, insertional success did not differ. One-year IUD continuation rates were similarly high in all groups.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.jpag.2025.08.007 | DOI Listing |
J Pediatr Adolesc Gynecol
September 2025
Division of Adolescent Medicine, Seattle Children's Hospital, Seattle, WA, USA.
Study Objectives: This study compares the demographic characteristics and experiences of three different groups of adolescent and young adults (AYAs) seeking non-sedated intrauterine device (IUD) insertion in the outpatient setting: (1) cisgender individuals, (2) transgender and gender diverse (TGD) individuals receiving gender-affirming testosterone therapy, and (3) TGD individuals not receiving gender-affirming testosterone therapy.
Methods: This retrospective cohort study included AYAs age 13 to 21 years seeking IUD insertion. Data were obtained from the electronic health record via a pre-existing, multi-institutional shared quality improvement (QI) collaborative.
J Voice
September 2025
Center for Speech and Language Sciences (CESLAS), Department of Rehabilitation Sciences, Ghent University, Ghent, Belgium; Department of Otorhinolaryngology and Head and Neck Surgery, Ghent University Hospital, Ghent, Belgium.
Introduction: A significant challenge for some transgender and gender diverse (TGD) individuals is that their voice and communication do not align with their gender identity or the way they wish to be perceived. Voice and communication training (VCT) can address key factors that are the most salient in gender perception, such as pitch, resonance, articulation, and intonation. While intonation training has proven its benefits for developing a feminine-sounding voice, its impact on achieving a masculine-sounding voice remains underexplored.
View Article and Find Full Text PDFClin J Am Soc Nephrol
September 2025
VA Greater Los Angeles Health Care System, Department of General Internal Medicine, Department of Medicine.
This review examines the effects of gender-affirming hormone therapy (GAHT) on kidney health in transgender and gender diverse (TGD) populations, which face significant challenges in accessing medical care. GAHT, typically involves estrogen therapy for transgender women and transfeminine individuals, testosterone therapy for transgender men and transmasculine individuals, and therapy regimens for individuals who are nonbinary or identify with another gender not culturally assigned to their sex assigned at birth. Hormone therapy influences biomarkers such as creatinine and cystatin C, which are used in estimating glomerular filtration rate (eGFR).
View Article and Find Full Text PDFJ Gen Intern Med
September 2025
Center for Transgender Medicine and Surgery, Mount Sinai Health System, New York, NY, USA.
Background: Few consensus guidelines exist regarding screening mammography recommendations for transgender and gender diverse (TGD) individuals.
Objective: Our study aimed to assess the utilization of screening mammograms in a large cohort of TGD individuals at a single institution and the factors influencing mammogram uptake.
Design: Retrospective cross-sectional study.
J Minim Invasive Gynecol
August 2025
Department of Obstetrics & Gynaecology, Radboud University Medical Center, Nijmegen, Netherlands.
Objective: to assess the prevalence of surgically confirmed endometriosis among assigned-female-at-birth (AFAB) transgender and gender diverse (TGD) individuals undergoing laparoscopic pelvic surgery.
Design: retrospective multicenter cohort study from 2021 to 2024.
Setting: three academic medical centers in the Netherlands and the United Kingdom.